Pivotal Therapeutics Granted U.S. Patent 8,715,648 for EPA:DHA formulation

Pivotal Therapeutics Inc. (CNSX:PVO,OTCQX:PVTTF) has been granted Patent Number 8,715,648 titled “Formulations Comprising Omega-3 Fatty Acids and Anti-Obesity Agent for the Reduction of Body Weight in Cardiovascular Disease Patients (CVD) and Diabetics”, by the U.S. Patent and Trademark Office.

As quoted in the press release:

This patent covers Pivotal’s unique formulation in conjunction with anti-obesity agents for the reduction of body weight in CVD patients and diabetics. This patent has terms that expire no earlier than 2031.

“This patent issuance represents an important step in further protecting and advancing the commercial potential of VASCAZEN®’s formulation,” said Dr. George Jackowski, Chairman and Chief Scientific Officer “Our unique 6:1 EPA:DHA formulation when used in combination with anti-obesity drugs may play a positive role in addressing Obesity,” added Dr. Jackowski.

Click here to read the Pivotal Therapeutics Inc. (CNSX:PVO,OTCQX:PVTTF) press release